Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 47,830	$ 39,467	$ 130,110	$ 116,414
Operating expenses
Cost of revenue	14,907	14,189	41,320	34,945
Research and development	35,658	36,072	110,534	107,644
Sales and marketing	21,513	24,949	71,887	68,769
General and administrative	20,755	20,154	66,099	51,156
Amortization of intangible assets	428	428	1,270	1,270
Total operating expenses	93,261	95,792	291,110	263,784
Loss from operations	(45,431)	(56,325)	(161,000)	(147,370)
Interest and other income, net	765	327	1,454	1,429
Interest expense	(653)		(653)
Net loss	(45,319)	(55,998)	(160,199)	(145,941)
Add: Net loss attributable to noncontrolling interest	38	95	136	95
Net loss attributable to Adaptive Biotechnologies Corporation	$ (45,281)	$ (55,903)	$ (160,063)	$ (145,846)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (0.32)	$ (0.40)	$ (1.12)	$ (1.04)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	142,928,654	140,833,564	142,334,342	140,060,379
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (0.32)	$ (0.40)	$ (1.12)	$ (1.04)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	142,928,654	140,833,564	142,334,342	140,060,379